Fintel on MSN7h
Cantor Fitzgerald Initiates Coverage of Acrivon Therapeutics (ACRV) with Overweight Recommendation
Fintel reports that on January 31, 2025, Cantor Fitzgerald initiated coverage of Acrivon Therapeutics (NasdaqGM:ACRV) with a Overweight recommendation. Analyst Price Forecast Suggests 260.44% Upside ...
Cantor Fitzgerald Reaffirms Their Buy Rating on Cigna (CI)
Cantor Fitzgerald analyst Sarah James maintained a Buy rating on Cigna (CI – Research Report) yesterday and set a price target of $350.00. The ...
Cantor Fitzgerald Upgrades Zevra Therapeutics (NASDAQ:ZVRA) to Strong-Buy
Cantor Fitzgerald upgraded shares of Zevra Therapeutics (NASDAQ:ZVRA – Free Report) to a strong-buy rating in a research note issued to investors on Wednesday,Zacks.com reports. Other equities ...
Cantor Fitzgerald maintains Vertex stock at Overweight, $480 target
Cantor Fitzgerald reiterated its Overweight rating and a $480.00 price target for Vertex Pharmaceuticals Incorporated (NASDAQ ...